Nitin Jain, MD, joins Chadi Nabhan, MD, MBA, FACP, Host of The HemOnc Pulse, to discuss unmet needs in CLL. The crew talk about AML and MDS in this episode of The HemOnc Pulse. Dr. Erba answers this question and more in this interview with Dr. Chadi Nabhan. Dr. Nath spoke transplant in patients with AML who are elderly and emphasized the need to include them in clinical trials. Dr. Cortes speaks about the plenary session he delivered during the Eleventh Annual Meeting of SOHO. The single-center study was conducted to address gaps in knowledge surrounding minority-predominant populations of patients. Enrolled patients must be aged 75 years or older or aged 18-74 years with specific comorbidities. The trial will enroll approximately 346 patients with treatment-naive TP53-mutated disease or biallelic 17p deletions. Dr. Konopleva explains the controversy and what she sees on the horizon for MRD in AML. Dr. Jabbour presented data from the study at the Eleventh Annual Meeting of SOHO. Dr. Brown shares what CLL news and session she's watching at the Eleventh Annual Meeting of SOHO. The award is the society’s “most prestigious award" and “serves to honor those that have been pioneers in their work." This single-center retrospective study looked at outcomes from 18 patients with AML treated with venetoclax plus an HMA. The study included 59 patients with T-ALL with a median age of 20 at diagnosis.